Emil Kongshøj Larsen, Executive Vice President for International Operations at Novo Nordisk, talks to BT about India’s role ...

The weight loss industry is experiencing its most dramatic transformation in decades. What started as a sector dominated by ...

Eli Lilly ( LLY 1.19%) and Novo Nordisk ( NVO 2.44%) are two of the leading companies in the fast-growing GLP-1 weight loss ...

By Brenden BobbyReader Columnist You’ve probably heard the catchy jingles for Ozempic, a miracle weight loss drug that has ...

Judges allow consolidation of vision loss lawsuits filed against Novo Nordisk and Eli Lilly over diabetes and weight loss ...

Geneticist Michael Klotsman was frustrated by human drug development. That led him to launch a startup focused on treatments ...

Real-world data show semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are linked with lower risk of major ...

Despite the widespread popularity of new weight-loss medications, research suggests a non-drug alternative is significantly ...

As physicians across specialties encounter increasing patient interest in GLP-1 receptor agonists, it is important for them ...

A new logo, typeface and dedicated GLP-1 medical program follow the company filing for bankruptcy in May following subscriber ...

A viral Instagram video has sparked a fitness feud after one trainer hit back, calling another’s advice “a dangerous message.

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...